SEC Tracker
Get the app

Cellectar Biosciences CLRB

Cellectar Biosciences reports Q3 2026 financial results

Cellectar Biosciences (CLRB) filed an 8-K with the SEC on Nov 10, 2026, 7:25 am ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Presented updated data at IWWM supporting iopofosine I 131 accelerated approval strategy
  2. Planned to dose first patients in Phase 3 trial in Q1 2027 and file for FDA accelerated approval in 1H 2027
  3. Published case study of complete response lasting over eight years in DLBCL patient

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Cellectar Biosciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.